公开(公告)号：WO2010129134A2

公开(公告)日：2010-11-11

申请号：PCT/US2010/030495

申请日：2010-04-09

Applicant: ULTRASOURCE, INC. ,  CASPER, Michael ,  HARE, Craig ,  COOK, Adam

Inventor： CASPER, Michael ,  HARE, Craig ,  COOK, Adam

IPC: H01L21/60

CPC classification number: B23K1/0016 ,  B23K1/19 ,  B23K1/20 ,  B23K26/382 ,  B23K26/40 ,  B23K35/0222 ,  B23K35/3013 ,  B23K2201/40 ,  B23K2203/16 ,  B23K2203/50 ,  B23K2203/52 ,  C23C14/046 ,  H05K1/0306 ,  H05K3/388 ,  H05K3/4038 ,  H05K2201/09827 ,  H05K2203/128 ,  Y10T29/49126

Abstract: The system contains a substrate having at least one electrical trace formed thereon. An opening is formed in the substrate. The opening comprising at least one wall. An electrically conductive fill is formed in the opening. The electrically conductive fill is chemically bonded to the wall and electrically contacted with the electrical trace.

Abstract translation: 该系统包含其上形成有至少一个电迹线的基板。 在基板上形成开口。 该开口包括至少一个壁。 在开口中形成导电填料。 导电填料化学键合到壁上并与电迹线电接触。

公开(公告)号：WO2018071447A1

公开(公告)日：2018-04-19

申请号：PCT/US2017/055983

申请日：2017-10-10

Applicant: ANDREWS, Steven W. ,  ARONOW, Sean ,  BLAKE, James F. ,  BRANDHUBER, Barbara J. ,  COOK, Adam ,  HAAS, Julia ,  JIANG, Yutong ,  KOLAKOWSKI, Gabrielle R. ,  MCFADDIN, Elizabeth A. ,  MCKENNEY, Megan L. ,  MCNULTY, Oren T. ,  METCALF, Andrew T. ,  MORENO, David A. ,  TANG, Tony P. ,  REN, Li

Inventor： ANDREWS, Steven W. ,  ARONOW, Sean ,  BLAKE, James F. ,  BRANDHUBER, Barbara J. ,  COOK, Adam ,  HAAS, Julia ,  JIANG, Yutong ,  KOLAKOWSKI, Gabrielle R. ,  MCFADDIN, Elizabeth A. ,  MCKENNEY, Megan L. ,  MCNULTY, Oren T. ,  METCALF, Andrew T. ,  MORENO, David A. ,  TANG, Tony P. ,  REN, Li

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00

Abstract: Provided herein are compounds of the Formula I and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X 1 , X 2 , X 3 , X 4 , Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract translation: 本文提供了式I的化合物及其立体异构体和药学上可接受的盐或溶剂合物，其中A，B，X 1，X 2， X 3，X 4，D环和E具有在说明书中给出的含义，其是RET激酶的抑制剂并且可用于治疗和预防 可以用RET激酶抑制剂治疗的疾病，包括与RET相关的疾病和病症。

公开(公告)号：WO2012071458A1

公开(公告)日：2012-05-31

申请号：PCT/US2011/061930

申请日：2011-11-22

Applicant: ARRAY BIOPHARMA INC. ,  GENENTECH, INC. ,  COOK, Adam ,  GUNAWARDANA, Indrani, W. ,  HUESTIS, Malcolm ,  HUNT, Kevin, W. ,  KALLAN, Nicholas, C. ,  METCALF, Andrew, T. ,  NEWHOUSE, Brad ,  SIU, Michael ,  TANG, Tony, P. ,  THOMAS, Allen, A. ,  VOLGRAF, Matthew

Inventor： COOK, Adam ,  GUNAWARDANA, Indrani, W. ,  HUESTIS, Malcolm ,  HUNT, Kevin, W. ,  KALLAN, Nicholas, C. ,  METCALF, Andrew, T. ,  NEWHOUSE, Brad ,  SIU, Michael ,  TANG, Tony, P. ,  THOMAS, Allen, A. ,  VOLGRAF, Matthew

IPC: C07D491/20 ,  C07D498/20 ,  C07D491/107 ,  C07D498/10 ,  C07D513/10 ,  C07D513/20 ,  A61K31/4439 ,  A61K31/527 ,  A61K31/444 ,  A61K31/506 ,  A61K31/424 ,  A61K31/429 ,  A61K31/437 ,  A61P25/28

CPC classification number: C07D498/20 ,  C07D491/107 ,  C07D491/20 ,  C07D498/10 ,  C07D513/10 ,  C07D513/20

Abstract: The invention provides novel tricyclic compounds of Formula I' that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.

Abstract translation: 本发明提供抑制APP的β-分泌酶切割的新颖的式I'三环化合物，并且可用作治疗神经变性疾病的治疗剂。

公开(公告)号：WO2019075092A1

公开(公告)日：2019-04-18

申请号：PCT/US2018/055255

申请日：2018-10-10

Applicant: EARY, Charles Todd ,  SPENCER, Stacey ,  CRANE, Zack ,  CHANDO, Katelyn ,  ASSELIN, Sylvie ,  LIU, Weidong ,  WELCH, Mike ,  COOK, Adam ,  KOLAKOWSKI, Gabrielle R. ,  METCALF, Andrew T. ,  MORENO, David A. ,  TANG, Tony P.

Inventor： EARY, Charles Todd ,  SPENCER, Stacey ,  CRANE, Zack ,  CHANDO, Katelyn ,  ASSELIN, Sylvie ,  LIU, Weidong ,  WELCH, Mike ,  COOK, Adam ,  KOLAKOWSKI, Gabrielle R. ,  METCALF, Andrew T. ,  MORENO, David A. ,  TANG, Tony P.

IPC: C07D471/04 ,  C07D519/00

Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.

公开(公告)号：WO2011130741A1

公开(公告)日：2011-10-20

申请号：PCT/US2011/032894

申请日：2011-04-18

Applicant: ARRAY BIOPHARMA INC. ,  GENENTECH, INC. ,  COOK, Adam ,  HUNT, Kevin, W. ,  LYSSIKATOS, Joseph, P. ,  METCALF, Andrew, T. ,  RIZZI, James, P. ,  TANG, Tony, P.

Inventor： COOK, Adam ,  HUNT, Kevin, W. ,  LYSSIKATOS, Joseph, P. ,  METCALF, Andrew, T. ,  RIZZI, James, P. ,  TANG, Tony, P.

IPC: C07D491/20 ,  C07D491/107 ,  A61K31/4188 ,  A61P25/28

CPC classification number: C07D491/107 ,  C07D491/20

Abstract: The invention provides novel tricyclic compounds of Formula (I) that inhibit B-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.

Abstract translation: 本发明提供抑制APP的B-分泌酶切割的新颖的式（I）三环化合物，并且可用作治疗神经变性疾病的治疗剂。

公开(公告)号：WO2011072064A1

公开(公告)日：2011-06-16

申请号：PCT/US2010/059553

申请日：2010-12-08

Applicant: ARRAY BIOPHARMA INC. ,  HUNT, Kevin, W. ,  RIZZI, James, P. ,  COOK, Adam

Inventor： HUNT, Kevin, W. ,  RIZZI, James, P. ,  COOK, Adam

IPC: C07D491/00

CPC classification number: C07D491/10

Abstract: The invention provides novel spirochroman compounds of Formulas I and II that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.

Abstract translation: 本发明提供抑制APP的分泌酶切割的新颖的式I和II的螺二色素化合物，并且可用作治疗神经变性疾病的治疗剂。

公开(公告)号：WO2010075200A1

公开(公告)日：2010-07-01

申请号：PCT/US2009/068672

申请日：2009-12-18

Applicant: ARRAY BIOPHARMA INC. ,  COOK, Adam ,  HUNT, Kevin, W. ,  DELISLE, Robert Kirk ,  ROMOFF, Todd ,  CLARK, Christopher, T. ,  KIM, Ganghyeok ,  CORRETTE, Christopher, P. ,  DOHERTY, George, A. ,  BURGESS, Laurence, E.

Inventor： COOK, Adam ,  HUNT, Kevin, W. ,  DELISLE, Robert Kirk ,  ROMOFF, Todd ,  CLARK, Christopher, T. ,  KIM, Ganghyeok ,  CORRETTE, Christopher, P. ,  DOHERTY, George, A. ,  BURGESS, Laurence, E.

IPC: C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  A61K31/353 ,  A61P29/00

CPC classification number: C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12

Abstract: Compounds of Formula I: (I) in which A, A 1 , R 1 , R 7a , R 7b , R 8 and R 10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D 2 (PGD 2 ). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.

Abstract translation: 其中A，A1，R1，R7a，R7b，R8和R10具有本说明书中给出的含义的式I化合物：（I）是可用于治疗和预防免疫疾病的DP2受体抑制剂， 过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎，以及由前列腺素D2（PGD2）介导的其他炎性疾病。 式I化合物还可用于通过产生IL-4，IL-5和/或IL-13来治疗涉及Th2T细胞的疾病或医学病症。

公开(公告)号：WO2020081848A1

公开(公告)日：2020-04-23

申请号：PCT/US2019/056786

申请日：2019-10-17

Applicant: ARRAY BIOPHARMA INC. ,  BLAKE, James F. ,  BOYS, Mark Laurence ,  CHICARELLI, Mark Joseph ,  COOK, Adam ,  ELSAYED, Mohamed S. A. ,  FELL, Jay B. ,  FISCHER, John P. ,  HINKLIN, Ronald Jay ,  MCNULTY, Oren T. ,  MEJIA, Macedonio J. ,  RODRIGUEZ, Martha E. ,  WONG, Christina E.

Inventor： BLAKE, James F. ,  BOYS, Mark Laurence ,  CHICARELLI, Mark Joseph ,  COOK, Adam ,  ELSAYED, Mohamed S. A. ,  FELL, Jay B. ,  FISCHER, John P. ,  HINKLIN, Ronald Jay ,  MCNULTY, Oren T. ,  MEJIA, Macedonio J. ,  RODRIGUEZ, Martha E. ,  WONG, Christina E.

IPC: C07D401/04 ,  C07D471/04 ,  C07D519/00 ,  A61P35/00 ,  A61K31/498 ,  A61K31/4985

Abstract: Compounds of Formula la or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases in the view of their ability to inhibit SHP2. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro , in situ , and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：WO2018071454A1

公开(公告)日：2018-04-19

申请号：PCT/US2017/055993

申请日：2017-10-10

Applicant: ANDREWS, Steven W. ,  ARONOW, Sean ,  BLAKE, James F. ,  BRANDHUBER, Barbara J. ,  COLLIER, James ,  COOK, Adam ,  HAAS, Julia ,  JIANG, Yutong ,  KOLAKOWSKI, Gabrielle R. ,  MCFADDIN, Elizabeth A. ,  MCKENNEY, Megan L. ,  MCNULTY, Oren T. ,  METCALF, Andrew T. ,  MORENO, David A. ,  RAMANN, Ginelle A. ,  TANG, Tony P. ,  REN, Li ,  WALLS, Shane M.

Inventor： ANDREWS, Steven W. ,  ARONOW, Sean ,  BLAKE, James F. ,  BRANDHUBER, Barbara J. ,  COLLIER, James ,  COOK, Adam ,  HAAS, Julia ,  JIANG, Yutong ,  KOLAKOWSKI, Gabrielle R. ,  MCFADDIN, Elizabeth A. ,  MCKENNEY, Megan L. ,  MCNULTY, Oren T. ,  METCALF, Andrew T. ,  MORENO, David A. ,  RAMANN, Ginelle A. ,  TANG, Tony P. ,  REN, Li ,  WALLS, Shane M.

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00

Abstract: Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X 1 , X 2 , X 3 , X 4 , Ring D, E, R a , R b , n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract translation: 本文提供了式I的化合物：（I）或其药学上可接受的盐或溶剂合物，其中A，B，X 1，X 2， X 3，X 4，D环，E，R a，R b，n和 m具有在说明书中给出的含义，它们是RET激酶的抑制剂，并且可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括RET相关的疾病和病症。

公开(公告)号：WO2011123674A1

公开(公告)日：2011-10-06

申请号：PCT/US2011/030769

申请日：2011-03-31

Applicant: ARRAY BIOPHARMA INC. ,  GENENTECH, INC. ,  CLARK, Christopher, T. ,  COOK, Adam ,  GUNAWARDANA, Indrani, W. ,  HUNT, Kevin W. ,  KALLAN, Nicholas, C. ,  SIU, Michael ,  THOMAS, Allen, A. ,  VOLGRAF, Matthew

Inventor： CLARK, Christopher, T. ,  COOK, Adam ,  GUNAWARDANA, Indrani, W. ,  HUNT, Kevin W. ,  KALLAN, Nicholas, C. ,  SIU, Michael ,  THOMAS, Allen, A. ,  VOLGRAF, Matthew

IPC: C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07D413/10 ,  C07D417/10 ,  C07D263/64 ,  A61K31/41 ,  A61P25/28

CPC classification number: C07D401/14 ,  C07D263/64 ,  C07D401/10 ,  C07D403/10 ,  C07D413/10 ,  C07D417/10

Abstract: The invention provides novel spirotetrahydronaphthalene compounds of Formula α that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.

Abstract translation: 本发明提供新颖的抑制APP分泌​​酶切割的式（a）的四氢四氢化合物，可用作治疗神经变性疾病的治疗剂。